• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Household Transmission of Influenza (H1N1-2009) in Japan: Age-specificity and Reduction of Household Transmission Risk by Zanamivir Treatment

tetano

Editor, Senior Moderator
J Int Med Res. 2011;39(2):619-28.
Household Transmission of Influenza (H1N1-2009) in Japan: Age-specificity and Reduction of Household Transmission Risk by Zanamivir Treatment.
Nishiura H, Oshitani H.
Source

PRESTO, Japan Science and Technology Agency, Saitama, Japan; Theoretical Epidemiology, University of Utrecht, Utrecht, The Netherlands.
Abstract

This study investigated household transmission data for influenza (H1N1-2009) in Japan in order to quantify the age-specific risk of infection and estimate the impact of antiviral treatment on the risk of household transmission. Among a total of 1547 households, involving 4609 household contacts, the secondary attack ratio (SAR) was estimated to be 11.4%. School children aged 5 - 18 years dominated the index cases. Age-specific infectiousness and susceptibility were highest among 0 - 4-year olds, with SAR estimated at 19.4% and 29.6%, respectively. Zanamivir treatment within 24 and 24 - 48 h of illness onset in index cases, respectively, reduced the risk of household transmission to 0.57 (95% CI 0.44, 0.73) and 0.58 (95% CI 0.38, 0.86) times that among those receiving the same treatment at > 48 h and those not receiving treatment. The preventive performance of antiviral treatment and prophylaxis should be further examined in randomized controlled trials.

PMID:
21672367
[PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/21672367
 
Back
Top Bottom